335 related articles for article (PubMed ID: 32128390)
1. Interfering MSN-NONO complex-activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer.
Qin Y; Chen W; Jiang G; Zhou L; Yang X; Li H; He X; Wang HL; Zhou YB; Huang S; Liu S
Sci Adv; 2020 Feb; 6(8):eaaw9960. PubMed ID: 32128390
[TBL] [Abstract][Full Text] [Related]
2. RNA-binding protein p54
Shen M; Zhang R; Jia W; Zhu Z; Zhao L; Huang G; Liu J
Cell Death Dis; 2022 Jan; 13(1):42. PubMed ID: 35013116
[TBL] [Abstract][Full Text] [Related]
3. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.
Chen J; Zhu M; Zou L; Xia J; Huang J; Deng Q; Xu R
Acta Biochim Biophys Sin (Shanghai); 2020 Aug; 52(8):801-809. PubMed ID: 32632453
[TBL] [Abstract][Full Text] [Related]
5. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
8. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
9. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.
Dutta P; Sarkissyan M; Paico K; Wu Y; Vadgama JV
Breast Cancer Res Treat; 2018 Aug; 170(3):477-486. PubMed ID: 29594759
[TBL] [Abstract][Full Text] [Related]
10. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
12. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.
Acharya S; Yao J; Li P; Zhang C; Lowery FJ; Zhang Q; Guo H; Qu J; Yang F; Wistuba II; Piwnica-Worms H; Sahin AA; Yu D
Cancer Res; 2019 Aug; 79(16):4211-4226. PubMed ID: 31239273
[TBL] [Abstract][Full Text] [Related]
14. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
15. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
16. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
[TBL] [Abstract][Full Text] [Related]
17. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
18. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
19. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
González-González A; Muñoz-Muela E; Marchal JA; Cara FE; Molina MP; Cruz-Lozano M; Jiménez G; Verma A; Ramírez A; Qian W; Chen W; Kozielski AJ; Elemento O; Martín-Salvago MD; Luque RJ; Rosa-Garrido C; Landeira D; Quintana-Romero M; Rosato RR; García MA; Ramirez-Tortosa CL; Kim H; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Lorente JA; Sánchez-Rovira P; Chang JC; Granados-Principal S
Clin Cancer Res; 2018 Nov; 24(22):5697-5709. PubMed ID: 30012564
[No Abstract] [Full Text] [Related]
20. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
Shen H; Yan W; Yuan J; Wang Z; Wang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
